Tien Liang BioTech Co., Ltd.

TPEX:4127 Stock Report

Market Cap: NT$1.9b

Tien Liang BioTech Past Earnings Performance

Past criteria checks 2/6

Tien Liang BioTech has been growing earnings at an average annual rate of 48.1%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 0.8% per year. Tien Liang BioTech's return on equity is 3.1%, and it has net margins of 3.5%.

Key information

48.1%

Earnings growth rate

48.1%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate0.8%
Return on equity3.1%
Net Margin3.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt?

Apr 19
Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt?

Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt

Jan 04
Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt

Revenue & Expenses Breakdown

How Tien Liang BioTech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4127 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24415152422
30 Jun 24426102511
31 Mar 24453192611
31 Dec 23460182661
30 Sep 23477262681
30 Jun 23490362721
31 Mar 23504412761
31 Dec 22529592771
30 Sep 22558702801
30 Jun 22595822851
31 Mar 22608832871
31 Dec 21571472941
30 Sep 2151872981
30 Jun 21455-323001
31 Mar 21423-623051
31 Dec 20431-523011
30 Sep 20452-262911
30 Jun 20450-332901
31 Mar 20446-312921
31 Dec 19436-473011
30 Sep 19452-903121
30 Jun 19478-1013232
31 Mar 19520-1033383
31 Dec 18534-943443
30 Sep 18518-663623
30 Jun 18494373892
31 Mar 18472-1964122
31 Dec 17515-2034512
30 Sep 17563-2304731
30 Jun 17641-3174881
31 Mar 17716-754892
31 Dec 16756-534812
30 Sep 16765-274742
30 Jun 16788-14603
31 Mar 16813244622
31 Dec 15841494602
30 Sep 1586367469-8
30 Jun 1588676461-5
31 Mar 1587574444-2
31 Dec 14844614281
30 Sep 148265240513
30 Jun 147944539414
31 Mar 148555342014
31 Dec 139184945315

Quality Earnings: 4127 has high quality earnings.

Growing Profit Margin: 4127's current net profit margins (3.5%) are lower than last year (5.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4127 has become profitable over the past 5 years, growing earnings by 48.1% per year.

Accelerating Growth: 4127's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4127 had negative earnings growth (-44%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.9%).


Return on Equity

High ROE: 4127's Return on Equity (3.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 09:14
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tien Liang BioTech Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.